Home Proteases Glutaminase

Glutaminase

Glutaminase Products

  • All (14)
  • Glutaminase Inhibitors (8)
  • Glutaminase Antagonists (4)
  • New Glutaminase Products
Catalog No. Product Name Information Product Use Citations Product Validations
S7655 Telaglenastat (CB-839) Telaglenastat (CB-839) is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. CB-839(Telaglenastat) inudces autophagy and has antitumor activity. Phase 1.
Clin Mol Hepatol, 2025, 10.3350/cmh.2024.0694
J Transl Med, 2025, 23(1):435
Cell Death Discov, 2025, 11(1):21
S7753 BPTES BPTES is a potent and selective Glutaminase GLS1 (KGA) inhibitor with IC50 of 0.16 μM. It has no effect on glutamate dehydrogenase activity and causes only a very slight inhibition of γ-glutamyl transpeptidase activity.
Signal Transduct Target Ther, 2025, 10(1):27
STAR Protoc, 2025, 6(1):103518
Gastroenterology, 2024, S0016-5085(24)00062-3
S8620 6-Diazo-5-oxo-L-norleucine 6-Diazo-5-oxo-L-norleucine (Diazooxonorleucine, L-6-Diazo-5-oxonorleucine, DON), an antibiotic isolated from Streptomyces, is a glutaminase antagonist with IC50 of ~1  mM for cKGA (kidney-type glutaminase). 6-Diazo-5-oxo-L-norleucine exhibits analgesic, antibacterial, antiviral and anticancer properties.
Int J Mol Sci, 2024, 25(18)10183
iScience, 2023, 26(10):107790
Cancer Cell, 2022, 40(10):1207-1222.e10
S8891 JHU-083 JHU-083 (Ethyl 2-(2-Amino-4-methylpentanamido)-DON) is a novel prodrug of DON.JHU-083 selectively blocks glutaminase activity in brain CD11b+ cells and prevents depression-associated behaviors induced by chronic social defeat stress.Solutions are unstable and should be fresh-prepared.
Cell Rep, 2025, 44(5):115596
iScience, 2023, 26(10):107790
S6417 GK921 GK921 is a transglutaminase 2 (TGase 2) inhibitor with an IC50 of 8.93 μM under a modified assay condition.
J Immunol Res, 2021, 2021:4754454
F1632New Glutaminase Rabbit mAb Glutaminase kidney isoform, mitochondrial, GLS, K-glutaminase, L-glutamine amidohydrolase, GLS1, KIAA0838, KGA, GAM, Glutaminase C, GAC
F3071New TGM2 Rabbit mAb TGM2,Transglutaminase 2
E0373New LDN-27219 LDN-27219 is a potent, reversible, slow-binding inhibitor of Tissue transglutaminase (TGase), which exhibits IC50 of 0.6 μM against human hTGase. It likely binds at the GTP-binding or regulatory site rather than the enzyme’s active site. It lowers blood pressure and improves endothelium-dependent vasodilation in resistance arteries in an age-dependent manner.
S8892 JHU395 JHU395 is a novel orally bioavailable GA (glutamine antagonists) prodrug designed to circulate inert in plasma, but permeate and release active GA within target tissues. JHU395 delivers active GA to malignant peripheral nerve sheath tumor (MPNST), and significantly inhibits tumor growth without observed toxicity.
S8778 UPGL00004 UPGL00004 is a potent glutaminase C (GAC) inhibitor with an IC50 of 29 nM, showing high selectivity for GAC over GLS2.
S8998 IACS-6274 IACS-6274 (IPN60090), is a potent, selective and orally active glutaminase inhibitor with potential antineoplastic and immunostimulating activities.
E2365 Glutaminase C-IN-1 Glutaminase C-IN-1 is an allosteric inhibitor of Glutaminase C (GAC) that inhibits cancer cell growth without affecting their normal cellular counterparts.
E1203 Sirpiglenastat Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. It has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response with immunomodulatory and antineoplastic activities.
E0134 L-Albizziin

L-albizziin (L-alpha-amino-beta-ureidopropionic acid) is a potent inhibitor of glutamase. L-albizziin interferes with the utilisation of L-glutamine by the Debaryomyces spp. enzyme probably in a competitive and reversible manner since L-albizziin is also a substrate of the enzyme.
S7655 Telaglenastat (CB-839) Telaglenastat (CB-839) is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. CB-839(Telaglenastat) inudces autophagy and has antitumor activity. Phase 1.
Clin Mol Hepatol, 2025, 10.3350/cmh.2024.0694
J Transl Med, 2025, 23(1):435
Cell Death Discov, 2025, 11(1):21
S7753 BPTES BPTES is a potent and selective Glutaminase GLS1 (KGA) inhibitor with IC50 of 0.16 μM. It has no effect on glutamate dehydrogenase activity and causes only a very slight inhibition of γ-glutamyl transpeptidase activity.
Signal Transduct Target Ther, 2025, 10(1):27
STAR Protoc, 2025, 6(1):103518
Gastroenterology, 2024, S0016-5085(24)00062-3
S6417 GK921 GK921 is a transglutaminase 2 (TGase 2) inhibitor with an IC50 of 8.93 μM under a modified assay condition.
J Immunol Res, 2021, 2021:4754454
E0373New LDN-27219 LDN-27219 is a potent, reversible, slow-binding inhibitor of Tissue transglutaminase (TGase), which exhibits IC50 of 0.6 μM against human hTGase. It likely binds at the GTP-binding or regulatory site rather than the enzyme’s active site. It lowers blood pressure and improves endothelium-dependent vasodilation in resistance arteries in an age-dependent manner.
S8778 UPGL00004 UPGL00004 is a potent glutaminase C (GAC) inhibitor with an IC50 of 29 nM, showing high selectivity for GAC over GLS2.
S8998 IACS-6274 IACS-6274 (IPN60090), is a potent, selective and orally active glutaminase inhibitor with potential antineoplastic and immunostimulating activities.
E2365 Glutaminase C-IN-1 Glutaminase C-IN-1 is an allosteric inhibitor of Glutaminase C (GAC) that inhibits cancer cell growth without affecting their normal cellular counterparts.
E0134 L-Albizziin

L-albizziin (L-alpha-amino-beta-ureidopropionic acid) is a potent inhibitor of glutamase. L-albizziin interferes with the utilisation of L-glutamine by the Debaryomyces spp. enzyme probably in a competitive and reversible manner since L-albizziin is also a substrate of the enzyme.
S8620 6-Diazo-5-oxo-L-norleucine 6-Diazo-5-oxo-L-norleucine (Diazooxonorleucine, L-6-Diazo-5-oxonorleucine, DON), an antibiotic isolated from Streptomyces, is a glutaminase antagonist with IC50 of ~1  mM for cKGA (kidney-type glutaminase). 6-Diazo-5-oxo-L-norleucine exhibits analgesic, antibacterial, antiviral and anticancer properties.
Int J Mol Sci, 2024, 25(18)10183
iScience, 2023, 26(10):107790
Cancer Cell, 2022, 40(10):1207-1222.e10
S8891 JHU-083 JHU-083 (Ethyl 2-(2-Amino-4-methylpentanamido)-DON) is a novel prodrug of DON.JHU-083 selectively blocks glutaminase activity in brain CD11b+ cells and prevents depression-associated behaviors induced by chronic social defeat stress.Solutions are unstable and should be fresh-prepared.
Cell Rep, 2025, 44(5):115596
iScience, 2023, 26(10):107790
S8892 JHU395 JHU395 is a novel orally bioavailable GA (glutamine antagonists) prodrug designed to circulate inert in plasma, but permeate and release active GA within target tissues. JHU395 delivers active GA to malignant peripheral nerve sheath tumor (MPNST), and significantly inhibits tumor growth without observed toxicity.
E1203 Sirpiglenastat Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. It has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response with immunomodulatory and antineoplastic activities.
F1632New Glutaminase Rabbit mAb Glutaminase kidney isoform, mitochondrial, GLS, K-glutaminase, L-glutamine amidohydrolase, GLS1, KIAA0838, KGA, GAM, Glutaminase C, GAC
F3071New TGM2 Rabbit mAb TGM2,Transglutaminase 2
E0373New LDN-27219 LDN-27219 is a potent, reversible, slow-binding inhibitor of Tissue transglutaminase (TGase), which exhibits IC50 of 0.6 μM against human hTGase. It likely binds at the GTP-binding or regulatory site rather than the enzyme’s active site. It lowers blood pressure and improves endothelium-dependent vasodilation in resistance arteries in an age-dependent manner.

Choose Selective Glutaminase Inhibitors

Tags: Glutaminase inhibitor|Glutaminase agonist|Glutaminase activator|Glutaminase inducer|Glutaminase antagonist|Glutaminase signaling pathway|Glutaminase assay kit